Tagrisso + chemo approved in China & Japan as 1st-line treatment for patients with EGFR-mutated advanced lung cancer July 1, 2024
Tagrisso granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer June 18, 2024
Tagrisso with the addition of chemo recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer June 11, 2024
Tagrisso + chemo showed favourable trend in OS in EGFR-mutated advanced lung cancer with further follow-up in FLAURA2 Ph 3 trial March 26, 2024
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer February 26, 2024
Tagrisso demonstrated efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Ph 3 trial February 26, 2024
Type II Extension of Indication Application to the EMA Seeking Approval of RYBREVANT + Lazertinib, for 1L Treatment of Patients with EGFR-Mutated NSCLC February 26, 2024
Application submitted to the EMA for RYBREVANT + Chemo for the Treatment of Adult Patients with Advanced EGFR-Mutated NSCLC After Failure of Prior Therapy December 11, 2023
Supplemental BLA submitted to FDA Seeking Approval of RYBREVANT + Chemo in EGFRm NSCLC Patients Who Progressed on or after Osimertinib December 4, 2023
Tagrisso plus chemo granted Priority Review in the US for patients with EGFR-mutated advanced NSCLC October 25, 2023
EXKIVITY® (mobocertinib) to be voluntary withdrawn from the U.S. for adult patients with EGFR Exon20 insertion+ mNSCLC whose disease has progressed on or after platinum-based chemotherapy October 11, 2023
Ph 3 MARIPOSA Study Meets Primary Endpoint of PFS for RYBREVANT (amivantamab-vmjw) + Lazertinib vs Osimertinib in EGFR-Mutated NSCLC October 3, 2023
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated mNSCLC in HERTHENA-Lung01 Ph 2 Trial September 19, 2023
Ph 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in PFS Improvement with RYBREVANT + Chemo +/- Lazertinib vs chemo Alone in Patients with EGFR-Mutated NSCLC after Disease Progression on Osimertinib September 13, 2023
Tagrisso plus chemotherapy extended mPFS by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial September 13, 2023
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With NSCLC Harboring EGFR Exon 20 Insertion Mutations August 9, 2023
Treatment with RYBREVANT® (amivantamab-vmjw) + Chemo Resulted in Statistically Significant PFS Improvement in Patients with 1L EGFR Ex 20 Ins Mutation-Positive NSCLC July 27, 2023
FDA clears FDA INDA for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer July 19, 2023
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919 June 6, 2023
Safety Review Committee Approval to Advance to Ph 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA + Tagrisso in Advanced NSCLC June 6, 2023
New Long-Term Data from the CHRYSALIS Study Show mPFS Not Reached after 33.6 Months of Follow-Up with 1L RYBREVANT + Lazertinib Combo in EGFR-Mutated Advanced NSCLC June 6, 2023
Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Ph 3 trial June 6, 2023
TAGRISSO + chemo demonstrated strong improvement in PFS for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial May 31, 2023
